Log In
Print this Print this

Sirturo, bedaquiline (TMC207) (formerly R207910)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionDiarylquinoline (DARQ) antibiotic
Molecular Target Mycobacterial F1F0-ATP synthase
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationTuberculosis
Indication DetailsTreat multidrug-resistant tuberculosis (MDR-TB); Treat tuberculosis (TB) infection
Regulatory Designation

U.S. - Accelerated Approval (Treat multidrug-resistant tuberculosis (MDR-TB));
EU - Biosimilar (Treat multidrug-resistant tuberculosis (MDR-TB));
EU - Orphan Drug (Treat multidrug-resistant tuberculosis (MDR-TB))


Global Alliance for TB Drug Development; Pharmstandard OJSC

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today